<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63644">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01745237</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008224</org_study_id>
    <secondary_id>DCMRC-8224a</secondary_id>
    <nct_id>NCT01745237</nct_id>
  </id_info>
  <brief_title>Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis</brief_title>
  <official_title>Detection and Prognostic Significance of Myocardial Damage Visualized by Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to determine the ability of cardiac magnetic
      resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were
      to undergo CMR in addition to routine clinical evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with sarcoidosis, cardiac death is a leading cause of mortality which may
      represent unrecognized cardiac involvement.  Cardiovascular magnetic resonance (CMR) can
      detect cardiac involvement including minute amounts of myocardial damage. Therefore, the
      objective of this study was to determine the usefulness of CMR and compare it with standard
      clinical evaluation for cardiac involvement.  Patients with documented extracardiac
      sarcoidosis or clinically suspected cardiac sarcoidosis will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2002</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Major adverse cardiac events (MACE).</measure>
    <time_frame>greater than 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>&gt; 1year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac mortality</measure>
    <time_frame>&gt; 1year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary mortality</measure>
    <time_frame>&gt; 1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>only in subset of patients with pulmonary sarcoidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Transplant</measure>
    <time_frame>&gt; 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Transplant</measure>
    <time_frame>&gt; 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD/PPM placement</measure>
    <time_frame>&gt; 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate ICD therapy</measure>
    <time_frame>&gt; 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Sarcoidosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with extra cardiac sarcoidosis (confirmed by biopsy) or suspected cardiac
        sarcoidosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven extra-cardiac sarcoidosis

          -  Suspected cardiac sarcoidosis

        Exclusion Criteria:

          -  Contraindication to MRI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond J Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han W Kim, MD</last_name>
    <phone>919-668-3539</phone>
    <email>kim00050@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raymond J. Kim, MD</last_name>
    <phone>919-668-3539</phone>
    <email>kim00049@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han W Kim, MD</last_name>
      <phone>919-668-3539</phone>
      <email>kim00050@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Raymond J Kim, MD</last_name>
      <phone>919-668-3539</phone>
      <email>kim00049@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond J Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. Epub 2009 Nov 2.</citation>
    <PMID>19884472</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoidosis</keyword>
  <keyword>Cardiac Magentic Resonance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
